— Know what they know.
Not Investment Advice

PMCB NASDAQ

PharmaCyte Biotech, Inc.
1W: -9.3% 1M: -16.8% 3M: -45.2% YTD: -45.8% 1Y: -59.2% 3Y: -80.9% 5Y: -87.9%
$0.40
-0.00 (-0.94%)
 
Weekly Expected Move ±11.5%
$0 $0 $0 $0 $0
NASDAQ · Healthcare · Biotechnology · Tech Score Sell · Power 24 · $4.3M mcap · 10M float · 1.81% daily turnover · Short 21% of daily vol

Balance Sheet Trends

Total Assets
$47M -15.3% ▼
5Y CAGR: +44.6%
Total Liabilities
$12M +259.2% ▲
5Y CAGR: +74.6%
Shareholders Equity
$33M -35.8% ▼
5Y CAGR: +37.9%
Cash & Investments
$37M +138.7% ▲
5Y CAGR: +75.9%
Total Debt
$0 +0.0% ▲
Net Debt
-$19M -22.6% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2022FY2023FY2024FY2025FY2026
— Assets —
Cash$85M$68M$50M$15M$19M
Short-Term Investments$0$0$0$366K$18M
Cash & ST Investments$85M$68M$50M$16M$37M
Net Receivables$0$0$0$4M$241K
Inventory$0$0$0$0$0
Other Current Assets$0$0$260K$3M$97K
Total Current Assets$85M$68M$50M$22M$37M
Property, Plant & Equip.$0$0$0$0$0
Goodwill & Intangibles$4M$4M$2M$2M$0
Long-Term Investments$2M$2M$8M$22M$0
Other Non-Current Assets$8K$8K$8K$9M$9M
Total Non-Current Assets$5M$5M$9M$33M$9M
Total Assets$91M$73M$60M$55M$47M
— Liabilities —
Accounts Payable$205K$128K$389K$399K$271K
Short-Term Debt$0$0$0$0$0
Deferred Revenue$0$0$0$0$0
Other Current Liabilities$381K$345K$7M$0$0
Total Current Liabilities$704K$587K$7M$3M$826K
Long-Term Debt$0$0$0$0$0
Other Non-Current Liab.$0$0$13M$363K$9M
Total Non-Current Liabilities$0$0$13M$363K$9M
Total Liabilities$704K$587K$20M$3M$12M
— Equity —
Common Stock$2K$2K$2K$2K$3K
Retained Earnings-$112M-$116M-$116M-$85M-$104M
Accumulated OCI-$16K-$23K-$24K-$24K-$21K
Total Stockholders Equity$90M$73M$40M$52M$33M
Total Liabilities & Equity$91M$73M$60M$55M$47M
— Key Metrics —
Total Debt$0$0$0$0$0
Net Debt-$85M-$68M-$50M-$15M-$19M
Total Investments$2M$2M$8M$23M$18M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms